NCT03507101|Unknown
Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR)
DICAR
Loading search results
DICAR
Sponsor study identifier
observational
45
1 country
2
Study Start
August 1, 2018
Actual (reported)Primary Completion
July 1, 2021
Actual (reported)Study Completion
December 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of this study is to gain important knowledge on the pathogenesis and prognostic factors in severe invasive group A streptococcal (GAS) infections, as well as the effects of individual characteristics of both the pathogen and the patient on disease severity. The aim is to recruit a minimum of 60 patients from Tampere and Turku University Hospitals in 2-3 years to gather a suitably wide spectrum of manifestations of the disease, and gather genetic, transcriptomic and diagnostic data on both the patients and pathogens in an effort to further our understanding of the pathogenesis of severe invasive GAS disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 19, 2018
Actual (reported)April 24, 2018
Actual (reported)August 1, 2018
Actual (reported)July 1, 2021
Actual (reported)December 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Severe invasive GAS disease
GAS infection leading to death, complications or disability
Four month follow up
No particular intervention or exposure is of particular interest
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
A minimum of 60 patients from Tampere and Turku University Hospitals who contract invasive group A streptococcal disease within our recruitment period. The size of the study population has been difficult to calculate exactly, but the investigators have gauged the size according to previous epidemiological data to have a population that has a wide variety of disease courses to get a good understanding of the pathogenesis, and that can be recruited within 2-3 years.
Tampere university hospital
Tampere, Pirkanmaa, 33521, Finland
Turku university hospital
Turku, Southwest Finland, 20521, Finland
Kailankangas V, Vilhonen J, Grondahl-Yli-Hannuksela K, Rantakokko-Jalava K, Seiskari T, Auranen K, Lonnqvist E, Virolainen M, Hyyrylainen HL, Oksi J, Syrjanen J, Vuopio J. Presence of Streptococcus pyogenes in the throat in invasive Group A Streptococcal disease: a prospective two-year study in two health districts, Finland. Infect Dis (Lond). 2023 Jun;55(6):405-414. doi: 10.1080/23744235.2023.2192287. Epub 2023 Apr 8.
The investigators will obtain DNA and RNA samples from all study patients for genetic and transcriptomic analysis to assess inherited risk factors and immunologic response.
Jaana Syrjänen, PhD
Tampere University Hospital
45 participants (actual enrollment reported by the registry).
First Submitted
April 19, 2018
First Posted
April 24, 2018
Study Start
August 1, 2018
Actual (reported)Establishment of a PDT Patient Registry
Contact the study team to confirm eligibility.
Primary Completion
July 1, 2021
Actual (reported)Study Completion
December 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 14, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: